Application Note: Emerging drug targets in cancer immunotherapy
Cancer is the second leading cause of death globally. Immunotherapy harnesses the immune system to fight cancer cells and has emerged as the first-line therapy (standard treatment) for many solid tumors.
Inspired by the great success of PD-1/PD-L1 inhibitors, researchers in industry and academia are collaborating to identify other novel target molecules, such as T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), CD47 and signal regulatory protein α (SIRPα), to maximize the efficacy of immunotherapy.
Download this Application Note by Sino Biological to learn more about:
- Anti-TIGIT agents under clinical development
- CD47/SIRPα inhibitors under clinical trials
- High polymorphism in the IgV domain of SIRPα
- Additional emerging immunotherapy targets
And much more!
Cancer immunotherapy is a rapidly advancing field. In addition to the aforementioned targets, promising anti-tumor efficacy and good safety profiles have been observed for preclinical and clinical-stage drugs that act on other emerging targets, including TIM-3, VISTA, LAG-3 and CD27. Because of the continued exploration of novel therapeutic targets or combination strategies, several truly effective new treatment strategies will be available to patients with cancer in the future.
Explore Sino Biological’s wide range of proteins and antibodies for targets in immunotherapy: Immunotherapy | Sino Biological
This content was provided by Sino Biological.
